综述

5-氮杂胞苷对肿瘤抑制作用研究*

  • 高冰 ,
  • 邵国
展开
  • 泰国格乐大学国际学院公共卫生学系,泰国曼谷 10220
邵国

收稿日期: 2023-11-07

  网络出版日期: 2024-04-19

基金资助

*国家自然科学基金(82060337,82071479,31860307);内蒙古自然科学基金(2020MS0807,02020MS08171);深圳市龙岗区医疗卫生科技计划项目(LGKCYLWS2021000033,LGKCYLWS2023025);深圳市科技计划计划项目基础研究面上项目(JCYJ20220531092412028, JCYJ20230807121306012)

Study on the inhibitory effect of 5-azacytidine on tumor

  • GAO Bing ,
  • SHAO Guo
Expand
  • Department of Public Health, International College, Krirk University, Bangkok 10220, Thailand

Received date: 2023-11-07

  Online published: 2024-04-19

摘要

DNA甲基化异常是肿瘤发生发展的重要机制之一。DNA甲基化是建立和维持组织特异性基因表达的核心,也是调控基因表达的机制,对肿瘤的发生起着重要作用,尤其是抑癌基因高甲基化的异常状态,在肿瘤的发生、诊断、鉴别、预后、治疗等方面具有重要意义。此外,DNA甲基化与去甲基化是可逆的过程。5-氮杂胞苷(5-Azacytidine)通过抑制DNA甲基转移酶,降低高甲基化抑癌基因的甲基化水平,从而达到肿瘤治疗的目标。5-氮杂胞苷在白血病、骨髓增生异常综合征、前驱性骨髓细胞肿瘤和实体肿瘤中,通过DNA去甲基化作用抑制细胞增殖,促使细胞分化,具有治疗潜力,但其生物利用度低且长期使用可能引起DNA损伤和细胞毒性,因此需要寻找更好的给药方法和剂量调控策略,以验证和优化其抗肿瘤疗效并推动临床应用。

本文引用格式

高冰 , 邵国 . 5-氮杂胞苷对肿瘤抑制作用研究*[J]. 包头医学院学报, 2024 , 40(4) : 87 -90 . DOI: 10.16833/j.cnki.jbmc.2024.04.016

Abstract

Abnormal DNA methylation is one of the important mechanisms of tumorigenesis and development. It is the core of establishing and maintaining tissue-specific gene expression, and also the mechanism of regulating gene expression, which plays an important role in tumorigenesis. In particular, the abnormal state of hypermethylation of tumor suppressor genes is of great significance in the occurrence, diagnosis, identification, prognosis and treatment of tumors. In addition, DNA methylation and demethylation are reversible processes. 5-Azacytidine can reduce the methylation level of hypermethylated tumor suppressor genes by inhibiting DNA methyltransferase, so as to achieve the goal of tumor treatment. In leukemia, myelodysplastic syndrome, precursor bone marrow cell tumors and solid tumors, 5-azacytidine inhibits cell proliferation and promotes cell differentiation through DNA demethylation, which has therapeutic potential. However, its low bioavailability and long-term use may cause DNA damage and cytotoxicity. Therefore, it is necessary to find better administration methods and dose regulation strategies to verify and optimize its anti-tumor efficacy and promote clinical application.

参考文献

[1] Issa JPJ, Kantarjian HM. Targeting DNA methylation[J]. Clin Cancer Res, 2009,15(12):3938-3946.
[2] Karahoca M, M0mparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy[J]. Clin Epigenetics, 2013,5(1):3.
[3] Devos D,Vanoverveld W. Decitabine: a historical review of the development of an epigenetic drug[J]. Ann Hematol, 2005,84(1):3-8.
[4] Phan NL, Trinh NV, Pham PV. Low concentrations of 5-aza-2′-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression[J]. Onco Targets Ther, 2016,9:49-59.
[5] Farrell C, Doolin K,Leary NO, et al. DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic-pituitary-adrenal axis activity and to early life emotional abuse[J]. Psychiatry Res, 2018,265:341-348.
[6] 陈华. 5-Aza-CdR在白血病治疗中的应用[J]. 临床血液学杂志,2001,14(4):187-189.
[7] Doamaral GCLS, Planello AC, Borgato G, et al. 5-Aza-CdR promotes partial MGMT demethylation and modifies expression of different genes in oral squamous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2019,127(5):425-432.
[8] 邱湘宁. DNA甲基化抑制剂5-氮杂胞苷和5-氮杂-2′-脱氧胞苷对编码和非编码RNA表达的影响[D]. 长沙:中南大学,2010.
[9] Azechi T, Sato F, Sudo R, et al. 5-aza-2′-Deoxycytidine, a DNA methyltransferase inhibitor, facilitates the inorganic phosphorus-induced mineralization of vascular smooth muscle cells[J]. J Atheroscler Thromb, 2014,21(5):463-476.
[10] Wigner P, Czarny P, Synowiece E, et al. Variation of genes involved in oxidative and nitrosative stresses in depression[J]. Eur Psychiatry, 2018,48:38-48.
[11] Stricker SH,Gotz M. DNA-methylation: master or slave of neural fate decisions[J]. Front Neurosci, 2018,12:5.
[12] Deng T, Zhang Y. Possible involvement of activation of P53/P21 and demethylation of RUNX 3 in the cytotoxicity against Lovo cells induced by 5-Aza-2′-deoxycytidine[J]. Life Sci, 2009,84(10):311-320.
[13] Karpf AR, Moore BC, Ririe TO, et al. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine[J]. Mol Pharmacol, 2001,59(4):751-757.
[14] Liu J, Xie YS, Wang FL, et al. Cytotoxicity of 5-Aza-2′-deoxycytidine against gastric cancer involves DNA damage in an ATM-P53 dependent signaling pathway and demethylation of P16(INK4A)[J]. Biomed Pharmacother, 2013,67(1):78-87.
[15] Scott H, Smith AE, Barker GR, et al. Contrasting roles for DNA methyltransferases and histone deacetylases in single-item and associative recognition memory[J]. Neuroepigenetics, 2017,9:1-9.
[16] Xiong H, Chen ZF, Liang QC, et al. Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling[J]. J Cell Mol Med, 2009,13(9B):3668-3679.
[17] Chatterjee B, Lin MH, Chen CC, et al. DNA demethylation by DNMT3A and DNMT3B in vitro and of methylated episomal DNA in transiently transfected cells[J]. Biochim Biophys Acta Gene Regul Mech, 2018,1861(11):1048-1061.
[18] Ansari J, Shackelford RE, Elosta H. Epigenetics in non-small cell lung cancer: from basics to therapeutics[J]. Transl Lung Cancer Res, 2016,5(2):155-171.
[19] Balgkouranidou I, Liloglou T, Lianidou ES. Lung cancer epigenetics: emerging biomarkers[J]. Biomark Med, 2013,7(1):49-58.
[20] Liu R, Zhang XH, Zhang K, et al. 5-Aza-2′-deoxycytidine inhibits retinoblastoma cell by reactivating epigenetically silenced RASSF1A gene[J]. Int J Ophthalmol, 2014,7(1):51-56.
[21] Nikbakht DM, Azarnezhad A, Hashemibeni B,et al.An effective concentration of 5-aza-CdR to induce cell death and apoptosis in human pancreatic cancer cell line through reactivating RASSF1A and up-regulation of bax genes[J]. Iran J Med Sci, 2018,43(5):533-540.
[22] Pan FP, Zhou HK, Bu HQ, et al. Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK[J]. Oncol Rep, 2016,35(4):1941-1949.
[23] Yang B, Yang AG, Gao B, et al. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells[J].Int J Clin Exp Pathol, 2015,8(10):12961-12966.
[24] Zhang HH, Huang B, Cao YH, et al. Role of 5-Aza-CdR in mitomycin-C chemosensitivity of T24 bladder cancer cells[J]. Oncol Lett, 2017,14(5):5652-5656.
[25] 田小莉,杨洁,杨静,等. 5-氮杂-2′-脱氧胞苷对小鼠海马神经元细胞系HT22细胞DNA甲基转移酶表达和细胞周期的影响[J]. 解剖学杂志,2018,41(4):404-408.
[26] 方建晨,苏祖兰,邱耕,等. 淋巴瘤Daudi细胞SHP-1甲基化及5-杂氮脱氧胞苷抑制性效应的研究[J]. 中华血液学杂志,2006,27(10):670-674.
[27] Maslov AY, Lee M, Gundry M, et al. 5-aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1[J]. Oncogene, 2012,31(50):5172-5179.
[28] Ramos MP, Wijetunga NA, Mclellan AS, et al. DNA demethylation by 5-aza-2′-deoxycytidine is imprinted, targeted to euchromatin, and has limited transcriptional consequences[J]. Epigenetics Chromatin, 2015,8:11.
[29] Zhang ZX, Yang J, Liu XL, et al. Effects of 5-Aza-2′-deoxycytidine on expression of pp1 in learning and memory[J]. Biomed Pharmacother, 2016,84:277-283.
[30] Giri AK, Aittokallio T. DNMT inhibitors increase methylation in the cancer genome[J]. Front Pharmacol, 2019,10:385.
[31] Alabdulla R, Lozano E, Macias RIR, et al. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib[J]. Br J Pharmacol, 2019,176(6):787-800.
[32] Guo W, Wang C, Guo YL, et al. RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma[J]. Clin Exp Metastasis, 2015,32(1):83-98.
[33] Xu HZ, Hao SJ, Zhang JM, et al. The formation and modification of chromatin-like structure of human parvovirus B19 regulate viral genome replication and RNA processing[J]. Virus Res, 2017,232:134-138.
[34] Maipeli G, Amato E, Dandrea M, et al. Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors[J]. BMC Cancer, 2011,11:351.
文章导航

/